PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
3.490
+0.070 (2.05%)
At close: Aug 13, 2025, 4:00 PM
3.490
0.00 (0.00%)
After-hours: Aug 13, 2025, 5:15 PM EDT
PolyPid Employees
As of December 31, 2024, PolyPid had 60 total employees, including 57 full-time and 3 part-time employees. The number of employees decreased by 2 or -3.23% compared to the previous year.
Employees
60
Change (1Y)
-2
Growth (1Y)
-3.23%
Revenue / Employee
n/a
Profits / Employee
-$575,417
Market Cap
35.57M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PYPD News
- 4 hours ago - PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 hours ago - PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 1 day ago - PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer - GlobeNewsWire
- 14 days ago - PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025 - GlobeNewsWire
- 4 weeks ago - PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market - GlobeNewsWire
- 2 months ago - PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewsWire
- 2 months ago - PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention - GlobeNewsWire
- 2 months ago - PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention - GlobeNewsWire